Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO-DKD trial of finerenone in type 2 diabetes with diabetic kidney disease
MOH_2017-01-31_000073Phase 3Completed
- Sponsor
- Bayer
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Finerenone once daily with Placebo once daily (2 arms). Primary endpoint: Cardiovascular outcomes. Started Aug 2015; status: completed.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2017-01-31_000073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-31_000073.